The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The evolving role of immunotherapy and frontline treatment strategies in DLBCL
Shinichi Makita, MD, National Cancer Center Hospital, Tokyo, Japan, shares insight into the current treatment landscape for newly diagnosed diffuse large B-cell lymphoma (DLBCL), highlighting recent advancements with POLAR-CHP and tafasitamab plus R-squared-CHOP. Dr Makita notes that immunotherapy and precision medicine are transforming the treatment landscape and have the potential to increase the proportion of patients who are cured. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
